Beijing's Genecast Completes $149 Million E Round for Cancer Diagnostics
October 29, 2020 at 06:47 AM EDT
Genecast ( Beijing ) Technology completed a $149 million Series E financing to develop its second-generation sequencing technology and bioinformatics. Founded in 2014, Genecast has developed a circulating tumor DNA detection technology to provide individualized cancer diagnoses. The E Round was led by China Structural Reform Fund, and joined by Taikang Asset Management, CCB Private Equity Investment Management, Hillhouse Capital’s VC unit GL Ventures and China Renaissance. More details.... Share this with colleagues: // //